Subtype
Esophageal and Gastroesophageal Junction Carcinoma
CI-CAN-00002608Explore in graph →
460 active trials11 approved drugs34 evidence items
- NCIt
- C203673
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00002608Explore in graph →
Clinical trials
1,310 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (120)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04660760 | Ramucirumab and Trifluridine/Tipiracil or Paclitaxel for the Treatment of Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer | recruiting | Phase 2 | 116 | Academic and Community Cancer Research UnitedOTHER | 1 | Apr 1, 2024 | clinicaltrials |
| NCT04768218 | BLI for the Diagnosis of Precancerous Conditions | completed | — | 102 | Instituto Portugues de Oncologia, Francisco Gentil, PortoOTHER | 1 | Mar 29, 2024 |
| clinicaltrials |
| NCT06231680 | Thalidomide Prevention or Treatment of Camrelizumab-induced Reactive Cutaneous Capillary Endothelial Proliferation (RCCEP) | unknown | Phase 2 | 132 | Henan Cancer HospitalOTHER_GOV | 1 | Mar 29, 2024 | clinicaltrials |
| NCT04682431 | A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors | terminated | Phase 1 | 127 | Ikena OncologyINDUSTRY | 1 | Mar 22, 2024 | clinicaltrials |
| NCT06162767 | Cancer of Esophagogastric Junction: Optimized Sweet Versus Ivor-Lewis | recruiting | N/A | 240 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Mar 21, 2024 | clinicaltrials |
| NCT03339843 | Multiorgan Metabolic Imaging Response Assessment of Abemaciclib(MiMe-A) | completed | Phase 2 | 85 | Jules Bordet InstituteOTHER | 2 | Mar 15, 2024 | clinicaltrials |
| NCT04062656 | Perioperative Immunotherapy vs. Chemo-immunotherapy in Patients With Advanced GC and AEG(IMAGINE) | unknown | Phase 2 | 21 | University Hospital, EssenOTHER | 1 | Mar 12, 2024 | clinicaltrials |
| NCT06187597 | Consolidation of Toripalimab After Chemoradiotherapy in Elderly Esophageal Cancer (EC-CRT-007)(EC-CRT-007) | recruiting | Phase 2 | 140 | Sun Yat-sen UniversityOTHER | 1 | Mar 12, 2024 | clinicaltrials |
| NCT06303583 | Neoadjuvant Chemoradiotherapy Followed by Sequential Immunotherapy for Thoracic Esophageal Squamous Cell Carcinoma(CRIS) | enrolling by invitation | Phase 1 / Phase 2 | 30 | Qiu GuoqinOTHER | 1 | Mar 12, 2024 | clinicaltrials |
| NCT06194734 | A Study of KC1036 Versus Investigator's Choice of Chemotherapy in Patients With Advanced Esophageal Cancer | recruiting | Phase 3 | 490 | Beijing Konruns Pharmaceutical Co., Ltd.INDUSTRY | 1 | Mar 7, 2024 | clinicaltrials |
| NCT05472857 | Clinical Study of CLDN18.2-targeting CAR T Cells in Advanced Solid Tumors With Positive CLDN18.2 Expression | unknown | Phase 1 | 30 | Suzhou Immunofoco Biotechnology Co., LtdINDUSTRY | 1 | Mar 6, 2024 | clinicaltrials |
| NCT06225921 | Neoadjuvant Adebrelimab With Dalpiciclib for Resectable Esophageal Squamous Cell Carcinomas | unknown | Phase 1 | 6 | West China HospitalOTHER | 1 | Mar 6, 2024 | clinicaltrials |
| NCT05069766 | Preoperative Marking of the Oral Resection Margin in Esophageal Cancer With a Surgical Fiducial Marker - First Experiences | completed | N/A | 10 | Rigshospitalet, DenmarkOTHER | 1 | Feb 23, 2024 | clinicaltrials |
| NCT05591053 | Utility and Usability of ActivSight™ Laser Speckle Imaging in Visualization of Tissue Perfusion and Blood Flow During Esophageal Surgery in Humans | unknown | N/A | 70 | Activ SurgicalINDUSTRY | 1 | Feb 21, 2024 | clinicaltrials |
| NCT02830594 | Pembrolizumab and Palliative Radiation Therapy in Treating Patients With Metastatic Esophagus, Stomach, or Gastroesophageal Junction Cancer | completed | Phase 2 | 14 | City of Hope Medical CenterOTHER | 1 | Feb 20, 2024 | clinicaltrials |
| NCT02918162 | Perioperative Chemo and Pembrolizumab in Gastric Cancer | completed | Phase 2 | 49 | Gulam ManjiOTHER | 1 | Feb 15, 2024 | clinicaltrials |
| NCT03990025 | Linked Color Imaging vs White Light Imaging for Detection of Gastric Cancer Precursors | completed | N/A | 90 | Changi General HospitalOTHER | 1 | Feb 15, 2024 | clinicaltrials |
| NCT04844385 | Toripalimab Plus Neoadjuvant Chemotherapy Combined With Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma | unknown | Phase 2 | 124 | Sun Yat-sen UniversityOTHER | 1 | Feb 9, 2024 | clinicaltrials |
| NCT01691625 | Concurrent Chemoradiation With or Without DC-CIK Immunotherapy in Treating Locally Advanced Esophageal Cancer | completed | N/A | 50 | Capital Medical UniversityOTHER | 1 | Feb 7, 2024 | clinicaltrials |
| NCT06190652 | Real-world Experience of ICIs Plus Chemotherapy With or Without Radiotherapy for Advanced ESCC.(REICRAE) | completed | — | 728 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Feb 5, 2024 | clinicaltrials |
| NCT06241066 | The Prognostic Value of Tertiary Lymphatic Structure in Esophageal Squamous Cell Carcinoma | completed | — | 359 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Feb 5, 2024 | clinicaltrials |
| NCT06241079 | Multi-institutional Analysis of Survival and Recurrence Patterns of Different Pathological Regression Types After Neoadjuvant Chemoradiotherapy or Radiotherapy for Esophageal Squamous Cell Carcinoma | completed | — | 582 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Feb 5, 2024 | clinicaltrials |
| NCT04074343 | TAS-102 and Irinotecan in 2L+ Gastric and Gastroesophageal Adenocarcinoma | completed | Phase 1 | 20 | University of California, IrvineOTHER | 1 | Feb 2, 2024 | clinicaltrials |
| NCT05743504 | Immunotherapy With CCRT Followed by Surgery for Locally Advanced ESCC Patients | unknown | Phase 1 / Phase 2 | 32 | National Taiwan University HospitalOTHER | 1 | Feb 2, 2024 | clinicaltrials |
| NCT06238752 | First-line Apatinib Combined With Tislelizumab and Chemotherapy for Advanced GC(RENMIN-213) | completed | Phase 2 | 33 | Renmin Hospital of Wuhan UniversityOTHER | 1 | Feb 2, 2024 | clinicaltrials |
| NCT06222944 | Anlotinib, TQB2450 (PD-L1 Inhibitor), and Albumin-bound Paclitaxel Regimens in the Treatment of GC/GEJA | unknown | Phase 2 | 90 | Peking UniversityOTHER | 1 | Jan 25, 2024 | clinicaltrials |
| NCT03196232 | Epacadostat and Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal Junction or Gastric Cancer | completed | Phase 2 | 3 | George Albert FisherOTHER | 1 | Jan 23, 2024 | clinicaltrials |
| NCT05737563 | PD-1 Antibody Combined With mXELIRI Versus mXELIRI in the Second-line Setting for ESCC(Escape) | unknown | Phase 3 | 380 | Sun Yat-sen UniversityOTHER | 1 | Jan 23, 2024 | clinicaltrials |
| NCT03099382 | Study of SHR-1210 Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal Cancer | completed | Phase 3 | 457 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jan 22, 2024 | clinicaltrials |
| NCT04568200 | Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Resectable Esophageal Squamous Cell Carcinoma | completed | Phase 2 | 60 | Peking Union Medical College HospitalOTHER | 1 | Jan 22, 2024 | clinicaltrials |
| NCT02465736 | Study of Docetaxel or Vinorelbine Plus Cisplatin in Neoadjuvant Chemoradiotherapy for Esophageal Cancer (NEOCRTEC308) | unknown | Phase 3 | 610 | Sun Yat-sen UniversityOTHER | 1 | Jan 16, 2024 | clinicaltrials |
| NCT03600831 | Postoperative Concurrent Chemoradiotherapy Versus Radiotherapy Alone for Patients With Locoregionally Advanced Esophageal Squamous Cell Carcinoma | completed | Phase 2 / Phase 3 | 434 | Huai'an First People's HospitalOTHER | 1 | Jan 9, 2024 | clinicaltrials |
| NCT02037048 | FOLFOX-6 Induction Chemotherapy Followed by Esophagectomy and Post-operative Chemoradiotherapy in Patients With Esophageal Adenocarcinoma | unknown | Phase 2 | 63 | Case Comprehensive Cancer CenterOTHER | 1 | Jan 8, 2024 | clinicaltrials |
| NCT06190639 | A Clinical Study of Sintilimab as Adjuvant Therapy in Node-positive ESCC | recruiting | Phase 2 | 31 | Zhejiang Cancer HospitalOTHER | 1 | Jan 5, 2024 | clinicaltrials |
| NCT06190847 | Oral Microbiome is Associated With the Response to Chemoradiotherapy in Initial Inoperable Patients With Esophageal Squamous Cell Cancer | unknown | — | 97 | Anhui Provincial HospitalOTHER_GOV | 1 | Jan 5, 2024 | clinicaltrials |
| NCT05626569 | Anti-PD-1 Immunotherapy Combined With SBRT for Patients With Oligometastatic ESCC | unknown | Phase 2 | 40 | Sun Yat-sen UniversityOTHER | 1 | Jan 3, 2024 | clinicaltrials |
| NCT06186609 | PD-1 Inhibitor Combined With Radiotherapy for Elderly ESCC | unknown | Phase 2 | 68 | Affiliated Hospital of Nantong UniversityOTHER | 1 | Jan 2, 2024 | clinicaltrials |
| NCT04244552 | A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies | terminated | Phase 1 | 87 | Atreca, Inc.INDUSTRY | 1 | Dec 29, 2023 | clinicaltrials |
| NCT06125262 | Trajectory Analysis of NLR and Its Association With Efficacy of Immunochemotherapy in ESCC. | unknown | — | 100 | Guangdong Provincial People's HospitalOTHER | 1 | Dec 28, 2023 | clinicaltrials |
| NCT06184841 | HAIC Combined Sintilimab for Liver Metastasis From Esophageal Squamous Cell Carcinoma | completed | Phase 1 | 25 | Peking University Cancer Hospital & InstituteOTHER | 1 | Dec 28, 2023 | clinicaltrials |
| NCT05833594 | Whole-course Immunonutrition Combined With Chemoradiotherapy±ICIs for Local Advanced Patients With Inoperable Esophageal Squamous Cell Carcinoma | recruiting | — | 70 | Anhui Provincial HospitalOTHER_GOV | 1 | Dec 26, 2023 | clinicaltrials |
| NCT02916511 | Study of Extensive Clinical Target Volumes in Postoperative Radiotherapy Concurrent With Chemotherapy for Esophageal Squamous Cell Carcinoma(ESO-Shanghai9) | completed | Phase 2 | 70 | Fudan UniversityOTHER | 1 | Dec 22, 2023 | clinicaltrials |
| NCT06178211 | Neoadjuvant Adebrelimab Plus Chemotherapy for Resectable ESCC: a Single Arm, Prospective Phase 2 Clinical Trial | not yet recruiting | Phase 2 | 36 | Shanghai Chest HospitalOTHER | 1 | Dec 20, 2023 | clinicaltrials |
| NCT03783936 | Trial of mFOLFOX6 + Trastuzumab + Avelumab in Gastric and Esophageal Adenocarcinomas | completed | Phase 2 | 18 | Ashwin SomasundaramOTHER | 1 | Dec 19, 2023 | clinicaltrials |
| NCT06173986 | Immunotherapy in Combination With Chemoradiotherapy in Unresectable Locally Advanced Esophageal Cancer | recruiting | Phase 1 / Phase 2 | 50 | Shanghai Chest HospitalOTHER | 1 | Dec 18, 2023 | clinicaltrials |
| NCT06155383 | Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma. | recruiting | Phase 2 | 90 | RemeGen Co., Ltd.INDUSTRY | 1 | Dec 14, 2023 | clinicaltrials |
| NCT06163365 | Inherited Cancer Early Diagnosis (ICED) Study(ICED) | unknown | — | 100 | Royal Marsden NHS Foundation TrustOTHER | 1 | Dec 8, 2023 | clinicaltrials |
| NCT06152783 | Confocal Laser Microendoscopy (CellTouch) for the Diagnosis of Early Gastric Cancer: A Multicenter Clinical Study | unknown | — | 578 | Changhai HospitalOTHER | 1 | Dec 1, 2023 | clinicaltrials |
| NCT06152978 | A Perioperative Sintilimab and Chemotherapy in Esophageal Squamous Cell Carcinoma | not yet recruiting | Phase 2 | 182 | Fudan UniversityOTHER | 1 | Dec 1, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Apr 1, 2024source: clinicaltrials